Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Recombinant Asparaginase Erwinia chrysanthemi

            Therapeutic Area: Oncology Product Name: JZP458

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Bionical Emas

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 10, 2021


            JZP458 is launched for the treatment of adult and pediatric patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) following hypersensitivity or silent inactivation to E. coli-derived asparaginases.